# Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine (Bio Farma) in Adults and Children (Phase I)

> **NCT03109600** · PHASE1 · COMPLETED · sponsor: **PT Bio Farma** · enrollment: 100 (actual)

## Conditions studied

- Safety Issues

## Interventions

- **BIOLOGICAL:** Vi-DT (Bio Farma)
- **BIOLOGICAL:** Vi polysaccharide vaccine
- **BIOLOGICAL:** Influenzae vaccine
- **BIOLOGICAL:** Pneumococcal conjugate vaccine

## Key facts

- **NCT ID:** NCT03109600
- **Lead sponsor:** PT Bio Farma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-18
- **Primary completion:** 2017-09-28
- **Final completion:** 2018-02-19
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2018-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03109600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03109600, "Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine (Bio Farma) in Adults and Children (Phase I)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03109600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*